Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Triple Negative Breast Neoplasms × Goserelin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 111 Breast Neoplasms 75 Neoplasms 6 Breast Neoplasms, Male 6 Neoplasm Metastasis 4 Salivary Gland Neoplasms 3 Advanced Breast Cancer 3 Recurrence 2 Prostate Adenocarcinoma 2 Osteoporosis 2 Leiomyoma 2 Infertility 2 Advanced Prostate Cancer 2 Triple Negative Breast Neoplasms 1 Stage I Prostate Adenocarcinoma AJCC v7 1 Sexual Dysfunction, Physiological 1 Primary Ovarian Insufficiency 1 Primary Dysautonomias 1 PSA Level Greater Than Two 1 Ovarian Neoplasms 1 Osteitis Deformans 1 Myofibroma 1 Lymphatic Metastasis 1 Kidney Diseases 1 Inflammatory Breast Neoplasms 1 Hypertension 1 Hyperlipidemias 1 Hot Flashes 1 Hormone-sensitive Metastatic Breast Cancer 1 Hormone Sensitive Prostate Cancer 1

Interventions

pembrolizumab 126 Carboplatin 109 Paclitaxel 94 Cyclophosphamide 72 Capecitabine 53 130-nm albumin-bound paclitaxel 52 Doxorubicin 41 Gemcitabine 38 Albumin-Bound Paclitaxel 33 atezolizumab 32 Taxes 32 Nivolumab 29 Docetaxel 28 Cisplatin 28 sacituzumab govitecan 25 Epirubicin 25 Bevacizumab 24 eribulin 23 olaparib 22 Specimen Handling 22 durvalumab 21 Magnetic Resonance Spectroscopy 20 camrelizumab 19 Biopsy 19 Drug Therapy 18 toripalimab 16 Everolimus 13 spartalizumab 12 liposomal doxorubicin 12 Radiotherapy 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03444025 2018-02-23

NeoGONT

Kasr El Aini Hospital

Phase 2 Unknown

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡